Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates Pharmaceutical TechnologyBMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year's EHA conference.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaceutical Technology BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Altaris to acquire Simulations Plus in $375m all-cash deal Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
